Latest News on AMRX

Financial News Based On Company


Advertisement
Advertisement

FDA Approval for OXCARBAZEPINE issued to AMNEAL PHARMS

https://www.quantisnow.com/insight/fda-approval-for-oxcarbazepine-issued-to-amneal-pharms-6801425
The FDA approved a labeling supplement (SUPPL-26) for Amneal Pharmaceuticals' generic oxcarbazepine oral suspension on November 18, 2026. This approval updates the Medication Guide and Package Insert for an existing product and is considered a routine regulatory update rather than a new revenue-generating event for the company.

Amneal Pharmaceuticals stock hits 52-week high at 22.07 USD By Investing.com

https://in.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-hits-52week-high-at-2207-usd-93CH-5713296
Amneal Pharmaceuticals (AMRX) stock hit a new 52-week high of $22.07, raising its market capitalization to $7.64 billion. The company has shown strong performance with a 90.71% 1-year change and robust Q3 2026 results, exceeding analyst expectations for EPS and revenue. Despite a high P/E ratio, net income is projected to grow, although InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value.

Amneal Pharmaceuticals stock hits 52-week high at 22.07 USD

https://www.investing.com/news/company-news/amneal-pharmaceuticals-stock-hits-52week-high-at-2207-usd-93CH-5036777
Amneal Pharmaceuticals Inc. (AMRX) achieved a 52-week high of $22.07, marking a 90.71% increase over the past year and bringing its market capitalization to $7.64 billion. The company reported strong third-quarter 2026 results, exceeding Wall Street estimates for both adjusted earnings per share and revenue. Despite an InvestingPro analysis suggesting the stock may be overvalued relative to its Fair Value, Piper Sandler reiterated an "Overweight" rating with a $21.00 price target.

Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®

https://www.mycarrollcountynews.com/online_features/press_releases/article_3759315f-2e17-5441-b183-75542b560b35.html
Amneal Pharmaceuticals, Inc. announced that the European Commission (EC) has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®. This approval follows similar authorization in the UK and aims to expand access to high-quality, affordable biologic medicines across European markets. Adcomfo is approved for treating severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria in eligible patients.

Amneal Pharmaceuticals stock hits 52-week high at $21.74

https://www.investing.com/news/company-news/amneal-pharmaceuticals-stock-hits-52week-high-at-2174-93CH-5019375
Amneal Pharmaceuticals Inc. (AMRX) stock reached a new 52-week high of $21.74, reflecting an 82.02% increase over the past year and a 69.68% year-to-date return. The company recently surpassed analyst expectations in its third-quarter results, with adjusted diluted EPS of $0.26 and revenue of $862.7 million, leading to an upward revision in its future outlook. Despite trading above its Fair Value estimate according to InvestingPro, analysts like Piper Sandler have reiterated an "Overweight" rating with a $21.00 price target.
Advertisement

Amneal Pharmaceuticals stock hits 52-week high at $21.74 By Investing.com

https://ca.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-hits-52week-high-at-2174-93CH-4950511
Amneal Pharmaceuticals Inc. (AMRX) stock reached a new 52-week high of $21.74, currently trading at $21.82, reflecting an 82.02% increase over the past year and a 69.68% return year-to-date. The company recently reported strong third-quarter results, surpassing analyst expectations with adjusted diluted EPS of $0.26 and revenue of $862.7 million. Despite analysts revising earnings upwards, InvestingPro analysis indicates the stock trades above its Fair Value estimate, suggesting it might be overvalued.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A (AMRX) Earnings, Actual EPS, EPS Estimates & Results

https://stocktwits.com/symbol/AMRX/earnings
Amneal Pharmaceuticals Inc. (AMRX) reported Q3 '26 earnings, beating EPS estimates by 9.52% with a reported EPS of $0.26 against an estimated $0.24. The company also surpassed revenue estimates by 5.49%, reporting $862.68M. Following these results, Amneal increased its full-year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS.

Amneal Pharmaceuticals Q3 revenue rises 10% to $863M

https://grafa.com/en/news/united-states/amneal-pharmaceuticals-q3-2026-revenue-rises-10-percent
Amneal Pharmaceuticals reported a 10% increase in third-quarter 2026 revenue, reaching $863 million, despite recording a net loss of $22 million. Adjusted earnings per share rose 53% to $0.26, surpassing analyst expectations, and adjusted EBITDA climbed 30% to $207 million. The company raised its full-year revenue forecast to $3.15 billion–$3.25 billion but reduced its operating cash flow guidance.

Sales rose 10%, while Amneal reported a $22 million quarterly loss.

https://www.stocktitan.net/news/AMRX/amneal-reports-third-quarter-2026-financial-3t34nygjjoq3.html
Amneal Pharmaceuticals reported third-quarter 2026 revenue of $863 million, a 10% increase year-over-year, but recorded a net loss of $22 million, down from a net income of $2 million in the prior year. Despite the loss, adjusted EBITDA rose 30% to $207 million, and adjusted diluted EPS increased 53% to $0.26. The company also raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS, though it lowered its operating cash flow guidance due to higher inventory levels.

Amneal Reports Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/03/3394002/0/en/amneal-reports-third-quarter-2026-financial-results.html
Amneal Pharmaceuticals, Inc. announced strong third-quarter 2026 financial results, with net revenue increasing 10% to $863 million and adjusted EBITDA up 30% to $207 million. The company reported a GAAP net loss of $22 million and a diluted loss per share of $(0.06), but an adjusted diluted EPS of $0.26, a 53% increase. Amneal also updated its full-year 2026 guidance, raising projections for net revenue, adjusted EBITDA, and adjusted diluted EPS, citing accelerating performance driven by key product launches and the integration of Kashiv BioSciences.
Advertisement

Parkinson's Disease Therapeutics Market to Reach US$ 12.83 Billion by 2033, Driven by Advances in Neurological Treatments

https://www.openpr.com/news/4676718/parkinson-s-disease-therapeutics-market-to-reach-us-12-83
The global Parkinson's disease therapeutics market is projected to reach US$12.83 billion by 2033, growing at a CAGR of 8.1% from US$6.40 billion in 2025. This growth is fueled by an aging population, the need for long-term symptom management, and continuous investment in neurological drug development. North America currently leads the market, with the Asia-Pacific region showing the fastest growth.

Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark

https://www.tradingview.com/news/zacks:9b4d156bf094b:0-amarin-s-q3-earnings-beat-estimates-revenues-miss-mark/
Amarin Corporation reported adjusted earnings of eight cents per ADS for Q3 2026, surpassing the Zacks Consensus Estimate of a loss, despite a 57.9% year-over-year decline. However, total revenues of $39.6 million missed estimates due to lower U.S. product sales. The company's sole drug, Vascepa/Vazkepa, saw a global in-market demand increase of 55% year over year, and Amarin continued its strategic transformation through its partnership with Recordati in Europe.

Amneal Pharmaceuticals stock hits a USD 21.46 52-week high

https://www.ad-hoc-news.de/boerse/news/corporate-news/amneal-pharmaceuticals-stock-hits-a-usd-21-46-52-week-high/70423264
Amneal Pharmaceuticals (AMRX) reached a 52-week high of USD 21.46 on October 27, 2026, driven by strong Q2 revenue of USD 796.20 million and adjusted EPS of USD 0.30, surpassing analyst estimates. JPMorgan raised its price target for AMRX to USD 24.00, maintaining an "Overweight" rating. The company is set to release its third-quarter 2026 results on November 3, 2026, providing further insights into its financial performance.

Amneal Pharmaceuticals stock hits 52-week high at $21.18 By Investing.com

https://ca.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-hits-52week-high-at-2118-93CH-4906160
Amneal Pharmaceuticals Inc. (AMRX) stock has reached a new 52-week high of $21.18, more than doubling from its low of $9.99, demonstrating a 104.37% increase over the past year. The company's market capitalization is now $7.32 billion, although InvestingPro suggests it may be overvalued. Recent positive developments include strong Q2 earnings, an increased price target from UBS, and new coverage from Oppenheimer with an Outperform rating.

Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/AMRX/
This article provides a detailed stock overview for Amneal Pharmaceuticals, Inc. (AMRX), including its current stock price, recent performance, key financial metrics, and market data. It displays the stock's summary, news, chart, community sentiment, statistics, historical data, company profile, financials, analysis, options, and holders. The page also includes various valuation measures and financial highlights, such as profitability, income statement, balance sheet, and cash flow data.
Advertisement

Amneal Pharmaceuticals, Inc. Class A Estimates – SWB:2DT

https://www.tradingview.com/symbols/SWB-2DT/financials-estimates/
This page on TradingView provides financial estimates and actual data for Amneal Pharmaceuticals, Inc. Class A (SWB:2DT). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform offers tools for financial analysis and research for investors.

New preclinical data shows PRP can reprogram chemo-resistant pancreatic cancer cells to improve treatment response.

https://pluang.com/en/news-feed/propanc-biopharma-prp-reprogram-kanker-pankreas-resisten-kemoterapi
Propanc Biopharma announced new preclinical data indicating their pancreatic proenzyme formulation, PRP, can effectively reprogram chemotherapy-resistant pancreatic cancer cells, making them more susceptible to chemotherapy. The research revealed PRP's ability to reduce cancer cell proliferation, suppress metastasis, reverse resistance-linked cellular plasticity, and induce apoptosis. These findings support PRP's potential as a resistance-modulating therapy, with a Phase 1b clinical trial planned for Q1 2027 to improve outcomes for patients with advanced solid tumors.

Macleods, Amneal Recall Olanzapine, Exenatide Products in US Over Quality Issues

https://medicaldialogues.in/news/industry/pharma/macleods-amneal-recall-olanzapine-exenatide-products-in-us-over-quality-issues-180436
Macleods Pharmaceuticals Ltd and Amneal Pharmaceuticals of New York, LLC have initiated voluntary recalls of Olanzapine Tablets and Exenatide Injection prefilled pens, respectively, in the United States. Macleods recalled Olanzapine due to failed impurities and degradation specifications, affecting 15,744 bottles, while Amneal recalled 5,694 Exenatide pens due to a defective delivery system. Both are Class II recalls and concern prescription medicines distributed nationwide.

Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-amneal-pharmaceuticals-inc-class-a-for-23-september-93CH-4849121
This article announces the filing of a Form 4 for Amneal Pharmaceuticals Inc. Class A shares, dated September 23. Form 4 filings are used to report changes in beneficial ownership of securities by a company's directors, officers, and principal stockholders. The article primarily consists of navigation and market data, with the core content being the announcement itself.

Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September

https://in.investing.com/news/stock-market-news/form-4-amneal-pharmaceuticals-inc-class-a-for-23-september-93CH-5602330
This article reports on a Form 4 filing for Amneal Pharmaceuticals Inc Class A on September 23. Form 4s disclose changes in beneficial ownership of company stock by insiders. The article itself does not provide further details beyond the filing date and company name.
Advertisement

Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-amneal-pharmaceuticals-inc-class-a-for-23-september-93CH-4878774
This article announces the filing of Form 4 for Amneal Pharmaceuticals Inc Class A on September 23. It briefly mentions the company's stock symbol AMRX and its current performance with a -3.59% change. The content primarily consists of market data, news headlines, and navigational elements related to Investing.com.

Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-amneal-pharmaceuticals-inc-class-a-for-22-september-93CH-2703851
This article reports on a Form 4 filing for Amneal Pharmaceuticals Inc Class A, dated September 22, 2026. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's stock by its directors, officers, and principal stockholders. The article provides the title and publication date of this specific filing, indicating a significant insider transaction or ownership change for the company.

Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-amneal-pharmaceuticals-inc-class-a-for-22-september-93CH-4877222
This article announces the filing of Form 4 for Amneal Pharmaceuticals Inc. Class A on September 22. It is a brief, informative post indicating an insider transaction or change in beneficial ownership for the company, common for financial news outlets.

Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-amneal-pharmaceuticals-inc-class-a-for-22-september-93CH-4847555
This article from Investing.com announces a Form 4 filing for Amneal Pharmaceuticals Inc Class A, dated September 22. It provides no further details about the content of the Form 4, serving primarily as a notification of the filing. The article is very brief and mostly surrounded by website navigation and market data.

Amneal (NASDAQ: AMRX) director gifts 20,445 shares to trust he oversees

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-403526ae3fb7.html
Amneal Pharmaceuticals director J. Kevin Buchi gifted 20,445 shares of Class A Common Stock to a trust for which he serves as trustee. This transaction, reported on September 17, 2026, for no consideration, shifted a portion of his holdings from direct to indirect ownership. After the transfer, Buchi directly held 75,077 shares and indirectly held 113,944 shares through the trust.
Advertisement

Amneal Pharmaceuticals Director Kevin J. Buchi Transfers 20,445 Shares to Trust

https://kalkinemedia.com/us/news/announcements/amneal-pharmaceuticals-director-kevin-j-buchi-transfers-20445-shares-to-trust
Kevin J. Buchi, a director at Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), transferred 20,445 shares of Class A Common Stock to a trust on September 17, 2026, without consideration. Buchi, who acts as trustee for the recipient trust, directly holds 75,077 shares and indirectly holds 113,944 shares through the trust after this transaction. The transfer was reported in a Form 4 filing with the SEC on September 21, 2026.

Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD By Investing.com

https://uk.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-hits-52week-high-at-1932-usd-93CH-4876270
Amneal Pharmaceuticals (AMRX) stock reached a new 52-week high of $19.32, with an 88.05% increase over the past year. Despite its strong performance and positive market sentiment, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value. The company recently reported strong Q2 results, exceeding analyst expectations, and received FDA approval for a generic version of Ipsen's cancer treatment, further strengthening its market position.

Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD

https://www.investing.com/news/company-news/amneal-pharmaceuticals-stock-hits-52week-high-at-1932-usd-93CH-4909222
Amneal Pharmaceuticals (AMRX) stock reached a new 52-week high of $19.32, with a market capitalization of $6.62 billion, reflecting an 88.05% increase over the past year. Despite its current P/E ratio suggesting it might be overvalued, the company's net income is projected to grow this year. Recent positive developments include strong Q2 results, a raised price target from UBS, and FDA approval for its generic version of Ipsen's Somatuline.

Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD By Investing.com

https://in.investing.com/news/stock-market-news/amneal-pharmaceuticals-stock-hits-52week-high-at-1932-usd-93CH-5599885
Amneal Pharmaceuticals Inc. Class A stock recently hit a 52-week high of $19.32, with its market capitalization reaching $6.62 billion and total returns soaring to 90.72% over the past year. The company reported strong Q2 results, exceeding analyst expectations, and received FDA approval for its generic version of Ipsen’s Somatuline, further solidifying its market position. Despite a slight post-earnings stock decline due to near-term costs, analysts at UBS raised their price target, maintaining a "Buy" rating.

Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares

https://scanx.trade/stock-market-news/ipo/amneal-pharmaceuticals-files-prospectus-sale-up-28-9-million-shares/50018211
Amneal Pharmaceuticals has filed a prospectus with the SEC on August 14, 2026, for the potential sale of up to 28,942,098 shares of its Class A common stock by existing selling stockholders. This filing is intended to facilitate a liquidity event for these stockholders and does not include any financial performance metrics or operational updates from the company. The document outlines the terms under which these shares may be offered to investors.
Advertisement

Amneal (NASDAQ: AMRX) EVP gifts 152K shares to family trust

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-2da02f5ecb79.html
Amneal Pharmaceuticals, Inc. (AMRX) Executive Vice President Andrew S. Boyer gifted 152,426 shares of Class A Common Stock to a family trust on August 21, 2026. This bona fide gift, with a transaction price of $0.00 per share, means Boyer no longer serves as trustee for these shares. Following the transaction, Boyer's direct holdings amount to 273,646 shares of Class A Common Stock.

Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich

https://www.sahmcapital.com/news/content/amneal-pharmaceuticals-amrx-stock-looks-fairly-valued-but-earnings-still-look-rich-2026-08-21
Amneal Pharmaceuticals (AMRX) has seen a significant 344% gain over the past three years, leading to a valuation that appears less obviously cheap. The stock trades at a P/E ratio of 36.3x, more than double the industry average, yet its model-based fair P/E is close at 34.7x. The article highlights a split among investors, with some optimistic about biosimilar expansion and others concerned about execution risks and capital intensity.

Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance

https://www.sahmcapital.com/news/content/amneal-amrx-stock-looks-fairly-valued-following-raised-2026-guidance-2026-08-02
Amneal Pharmaceuticals (AMRX) has seen a 345.7% return over the past three years, leading to a valuation that appears fairly priced rather than an obvious bargain. While strong Q2 2026 results and raised full-year guidance support the current valuation, the stock trades at a P/E ratio of 37.1x, above the industry average, suggesting that much of the good news may already be factored in. The stock's future performance hinges on its ability to sustain strong earnings and margin growth to justify its premium valuation.

Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-20ea2294e0b8.html
Amneal Pharmaceuticals director John Kiely reported selling 50,000 shares of Class A Common Stock at a weighted average price of $17.64 per share on August 13, 2026. Additionally, he made a charitable donation of 10,000 shares of Class A Common Stock to a donor-advised fund on the same date. Following these transactions, Kiely directly holds 200,252 shares of Class A Common Stock.

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

https://kalkinemedia.com/us/news/announcements/amneal-pharmaceuticals-director-john-kiely-sells-50000-shares-and-donates-10000-shares-on-august-13-2026
John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company stands at 200,252 shares. The details were revealed in a Form 4 filing on August 14, 2026.
Advertisement

Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-4f3158634f07.html
Amneal Pharmaceuticals, Inc. (AMRX) reported that Tushar Bhikhubhai Patel, a greater-than-10% owner, indirectly acquired 12,763,469 Class A common shares through entities controlled by family trusts. This acquisition was part of Amneal's $375 million cash and stock purchase of Kashiv BioSciences, LLC, which also involved issuing 28,942,098 Amneal Class A shares. Following this transaction, Patel's associated entities now hold 61,341,678 Class A shares indirectly.

Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-e952d74e5a67.html
Amneal Pharmaceuticals director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on August 11, 2026. The shares were sold at a weighted average price of $17.18, with individual trades ranging from $17.07 to $17.31. Following this transaction, Buchi indirectly holds 93,499 shares through a trust and directly holds 75,077 shares.

What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders

https://www.sahmcapital.com/news/content/what-amneal-pharmaceuticals-amrxs-higher-guidance-and-complex-generics-pivot-means-for-shareholders-2026-08-14
Amneal Pharmaceuticals (AMRX) has raised its guidance for the second half of 2026, driven by a strategic pivot towards higher-value complex generics, biosimilars, and specialty medicines. Despite ongoing generic pricing pressures, the company projects significant revenue and earnings growth by 2029, with analysts anticipating a substantial upside to its current stock price. This shift aims to improve profitability and manage its debt load, though sustained success depends on new product launches and biosimilar approvals.

Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-84cbf7b0313f.html
Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, sold a total of 216,613 shares of Class A Common Stock in two separate transactions on August 11 and August 12, 2026. The sales were open-market transactions, not pursuant to a Rule 10b5-1 trading plan, and involved weighted average prices of $17.70 and $17.40 per share respectively. Following these transactions, Daly's direct holdings in Class A Common Stock are 35,171 shares.

Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A

https://www.stocktitan.net/sec-filings/AMRX/schedule-13d-a-amneal-pharmaceuticals-inc-amended-major-shareholder-r-c949a978ae87.html
Tushar Patel has filed an Amendment No. 6 to his Schedule 13D, disclosing beneficial ownership of 61,341,678 shares of Amneal Pharmaceuticals Class A common stock, representing 17.6% of the outstanding shares. This updated ownership stake reflects shares acquired through the recent Kashiv BioSciences acquisition, where Amneal issued 28,942,098 Class A shares to sellers, including those attributed to Patel. Patel's beneficial ownership includes holdings by TI SIE 2 and Rock Nola, LLC, an entity controlled by a trust associated with him.
Advertisement

Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares

https://www.stocktitan.net/sec-filings/AMRX/schedule-13d-a-amneal-pharmaceuticals-inc-amended-major-shareholder-r-914524f244d2.html
Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC for $375 million in cash and 28,942,098 shares of Class A Common Stock. This transaction has resulted in Chintu Patel becoming the beneficial owner of 32,576,528 shares, representing 9.4% of Amneal's Class A Common Stock. The filing details Patel's direct and indirect holdings, including shares held through trusts and entities like CKR Dynasty, LLC and Shivkan Holdings, LLC, which received a portion of the newly issued shares.

Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-837205d9dd6f.html
Amneal Pharmaceuticals director Gautam Patel reported an indirect acquisition of 283,632 Class A common shares on August 10, 2026. These shares were received by limited liability companies he manages as part of Amneal's acquisition of Kashiv BioSciences, LLC. Following this transaction, Patel directly holds 1,643,963 shares of Amneal.

Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal

https://www.stocktitan.net/sec-filings/AMRX/form-4-amneal-pharmaceuticals-inc-insider-trading-activity-d5f1e3bcb50a.html
Amneal Pharmaceuticals' Co-CEO, Chirag K. Patel, through entities he manages, acquired 6,381,734 Class A common shares on August 10, 2026. This share issuance was part of Amneal's acquisition of Kashiv BioSciences, LLC. After the transaction, Patel holds 1,393,470 shares directly and 21,269,420 shares indirectly through family trusts, in addition to the newly acquired shares via LLCs.

Amneal completes acquisition of Kashiv BioSciences

https://www.investing.com/news/company-news/amneal-completes-acquisition-of-kashiv-biosciences-93CH-4849006
Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) has completed its acquisition of Kashiv BioSciences LLC, integrating Kashiv's biologics research, development, and manufacturing capabilities with Amneal's commercial operations. This strategic move aims to position Amneal as a leading affordable medicines company and capitalize on the projected $300 billion global biosimilars market as biologics lose exclusivity over the next decade. The acquisition enhances Amneal's portfolio and market reach in the biosimilar sector.

Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality

https://www.sahmcapital.com/news/content/amneal-pharmaceuticals-nasdaqamrx-strong-earnings-are-of-good-quality-2026-08-07
Amneal Pharmaceuticals reported healthy earnings, but the stock price remained stable. The company's profit was impacted by US$81m in unusual expenses, which are likely one-off events, suggesting higher future profits. The article highlights that these unusual items might cause Amneal Pharmaceuticals' statutory profit to understate its true earnings potential and advises investors to consider other factors like margins and growth.
Advertisement

UBS raises Amneal Pharmaceuticals price target on biosimilar growth

https://www.investing.com/news/analyst-ratings/ubs-raises-amneal-pharmaceuticals-price-target-on-biosimilar-growth-93CH-4831741
UBS has increased its price target for Amneal Pharmaceuticals Inc. to $25.00 from $23.00, maintaining a Buy rating. This adjustment follows the company's strong second-quarter earnings beat and raised guidance, despite a recent stock pullback. UBS anticipates significant growth from Amneal's biosimilar and generic product approvals, with new launches expected to add $1 billion to $2 billion in incremental revenue by 2030.

Amneal Pharma A earnings beat by $0.07, revenue topped estimates

https://www.investing.com/news/earnings/amneal-pharma-a-earnings-beat-by-007-revenue-topped-estimates-4823371
Amneal Pharma A (NASDAQ: AMRX) reported strong second-quarter results, surpassing analyst estimates with EPS of $0.300 and revenue of $796.2 million. The company also provided optimistic full-year 2026 guidance, expecting EPS between $0.960-$1.060 and revenue between $3.100B-$3.200B. AMRX stock has shown significant growth, increasing by 48.870% in the last 3 months and 144.250% in the last 12 months.

Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure

https://www.sahmcapital.com/news/content/amneal-pharmaceuticals-amrx-stock-asks-if-profit-momentum-can-endure-2026-08-01
Amneal Pharmaceuticals (AMRX) reported a strong Q2 with increased revenue and adjusted EPS, leading to a raised full-year outlook. While the company is transitioning towards higher-margin biosimilars and injectables, investor concern centers on the sustainability of this profit momentum given increased capital expenditure and the need to close and realize benefits from the Kashiv deal. Bulls highlight execution proof points in their shift to higher-value assets, while bears focus on timing, leverage, and capacity risks, questioning if the current spending and insider selling are isolated issues or deeper strains.

Earnings call transcript: Amneal tops Q2 2026 estimates, but shares slip

https://www.investing.com/news/transcripts/earnings-call-transcript-amneal-tops-q2-2026-estimates-but-shares-slip-93CH-4824723
Amneal Pharmaceuticals reported stronger-than-expected Q2 2026 earnings and revenue, with adjusted EPS at $0.30 and revenue at $796.2 million, beating analyst estimates. Despite the strong performance and raised full-year guidance, the stock saw a slight premarket dip, potentially due to its proximity to its 52-week high and elevated investor expectations. The company highlights robust growth in affordable medicines and specialty segments, expansion into biosimilars, and progress in its GLP-1 manufacturing partnership with Pfizer as key long-term drivers.

Amneal Reports Second Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/07/30/3335845/0/en/Amneal-Reports-Second-Quarter-2026-Financial-Results.html
Amneal Pharmaceuticals reported strong second-quarter 2026 financial results, with net revenue increasing 10% to $796 million and diluted EPS rising 157% to $0.18. The company is raising its full-year 2026 guidance, driven by growth in its Specialty and Affordable Medicines segments and successful debt repricing. Amneal also highlighted the upcoming Kashiv acquisition, expected to establish biosimilars as a new growth area.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement